ClinicalTrials.gg
Not yet recruitingNCT07044661Updated Jul 1, 2025

Effect of Bilateral vs. Unilateral Alveolar Recruitment on Gas Exchange in Lung Resection

An interventional study of Unilateral ARM and Bilateral ARM in Lung Cancer Requiring Surgical Resection Under One-lung Ventilation, sponsored by Yonsei University. Not yet recruiting at 2 sites in South Korea. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-01.

Sponsored by Yonsei University · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
198
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Lung Neoplasms by Yonsei University — 3 open to participants now, 3 under way, none of them phase 3. Lung Neoplasms · Yonsei University.

Planned enrollment
Largest of 16
198 · median 53
Started
2025
the only one that year
No phase
8 of 18
2 open now
Registered
18th of 18
by date

Among the 18 studies in Lung Neoplasms by Yonsei University, this one has the largest planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2025, is one of 8 with no phase, and was the 18th registered.

Lung Neoplasms

5,434 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

3 of the 18 studies in Lung Neoplasms by Yonsei University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Lung Neoplasms by Yonsei University, or all of them as a file.
02

Study summary

"One-lung ventilation (OLV) is an essential technique during thoracic surgery but preventing atelectasis during OLV remains a key challenge in thoracic anesthesia.

Several previous randomized controlled trials have demonstrated that alveolar recruitment maneuvers (ARMs) can significantly reduce driving pressure, peak airway pressure, plateau pressure, and anatomical dead space. However, the optimal method for implementing ARMs has not yet been standardized, as the timing and target of ARM application vary among studies. Some protocols involve applying ARMs to both lungs immediately prior to the initiation of OLV (bilateral ARM), while others apply ARMs solely to the non-operative lung after OLV has begun (unilateral ARM). Bilateral ARM may provide prolonged improvement in gas exchange but carry the risk of insufficient collapse of the operative lung. Conversely, unilateral ARM may facilitate better collapse of the operative lung compared to bilateral ARMs, though potentially at the expense of gas exchange. To date, no study has directly compared these two approaches. This study aims to compare and evaluate the effects of bilateral versus unilateral ARM performed immediately prior to thoracic incision on intraoperative gas exchange and the incidence of intraoperative and postoperative complications."

03

Conditions studied

  • Lung Cancer Requiring Surgical Resection Under One-lung Ventilation

Browse trials for

04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -Adult patients aged 20 to 80 years scheduled for thoracoscopic lung resection.
  • (ASA) physical status classification of I to III.

Exclusion criteria

Exclusion Criteria:

  • Anticipated duration of one-lung ventilation (OLV) less than 1 hour.
  • Diagnosis of heart failure.
  • History of pneumothorax or radiologic evidence of pulmonary blebs or bullae prior to surgery.
  • Patients receiving supplemental oxygen therapy or mechanical ventilation prior to surgery.

Dropout Criteria

  • Actual duration of OLV less than 1 hour.
  • Surgery is canceled or converted to an open thoracotomy or another surgical approach.
  • Inability to maintain peripheral oxygen saturation ≥90% despite adjustments in inspired oxygen fraction.
  • Inability to maintain ventilator settings due to extensive pulmonary adhesions.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
198 participants (estimated)

Study arms

  • Active comparator
    Uni-ARM group

    Unilateral ARM is performed immediately after lateral decubitus positioning of the patient, followed by lung-protective mechanical ventilation with individualized PEEP.

    Procedure: Unilateral ARM

  • Experimental
    Bi-ARM group

    Bilateral ARM is performed immediately after lateral decubitus positioning of the patient, followed by lung-protective mechanical ventilation with individualized PEEP.

    Procedure: Bilateral ARM

Interventions

  • ProcedureUnilateral ARM

    ARM is performed to the dependent lung only. During ARM, mechanical ventilation is set to a pressure-controlled ventilation mode with a driving pressure of 20 cmH₂O and an inspiratory-to-expiratory ratio of 1:1. The positive end-expiratory pressure (PEEP) is increased by 5 cmH₂O every five respiratory cycles, reaching a final PEEP of 20 cmH₂O and a peak airway pressure of 40 cmH₂O, which is then maintained for ten respiratory cycles.

  • ProcedureBilateral ARM

    ARM is performed to both lungs. During ARM, mechanical ventilation is set to a pressure-controlled ventilation mode with a driving pressure of 20 cmH₂O and an inspiratory-to-expiratory ratio of 1:1. The positive end-expiratory pressure (PEEP) is increased by 5 cmH₂O every five respiratory cycles, reaching a final PEEP of 20 cmH₂O and a peak airway pressure of 40 cmH₂O, which is then maintained for ten respiratory cycles.

06

What researchers measure

Primary outcomes

  1. PaO₂/FiO₂ at 60 minutes after ARM

    We analyze whether different methods of ARM result in significant differences in the PaO₂/FiO₂ ratio measured at 60 minutes after the initiation of one-lung ventilation (OLV60).

    Time frame: PaCO₂ is assessed by arterial blood gas analysis at 60 minutes after ARM.

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2025; primary completion for Apr 2027, 21 months later.

Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 21 months is below that.

Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2025
First posted
Jul 1, 2025
StartEst.
Jul 10, 2025
Primary completionEst.
Apr 10, 2027
CompletionEst.
Jun 10, 2027
Last update
Jul 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07044661
Lead sponsor
Yonsei University
Responsible party
Sponsor
First posted
Jul 1, 2025
Start date
Jul 10, 2025 (estimated)
Primary completion
Apr 10, 2027 (estimated)
Completion
Jun 10, 2027 (estimated)
Last update
Jul 1, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion